Our Extended Family of Portfolio Companies

Investing in transformational ideas and entrepreneurial grit to solve major unmet needs in patient care

view more →

410 Medical is dedicated to developing innovative products that help emergency clinicians provide better care for critically ill patients.

view more →

AN2 is a biopharmaceutical company focused on developing novel medicines. IPO in March 2022 (NASDAQ: ANTX)

view more →

AtaCor Medical is developing a novel extracardiac pacing system that does not require leads or hardware to be placed inside or onto the heart.

view more →

Atsena Therapeutics is a clinical-stage, ophthalmology-focused gene therapy company

view more →

Avivomed engages in developing neuromodulation therapy intended to treat unmet clinical needs.

view more →

Developing first-in-class approach to activate myeloid cells to kill cancer. 

view more →

CVRx has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. IPO in June 2021 (NASDAQ: CVRX).

view more →

GoCheck Kids is the leading digital vision screening platform for children. 

view more →

Engages patients and families in a personalized way to initiate discussions on end-of-life care planning. Acquired by Aledade in January 2022.

view more →

Perfuse Therapeutics, Inc. is a seed stage biotechnology company focusing on improving retinal perfusion

view more →

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke.

view more →

SafeRide’s technology provides end-to-end data transparency while improving patient experience, population health, and program efficiency.

view more →

Shattuck Labs is a clinical-stage biotechnology company for the treatment of cancer and autoimmune disease. IPO in October 2020 (NASDAQ: STTK)

view more →

Tune strives to develop paradigm-changing cell and gene therapies.

view more →

The company’s lead drug has potential to be a game-changer in the treatment of HITT. Acquired by Cadrenal Therapeutics 2025

view more →

Vigil Neuroscience is the world’s first microglia-focused therapeutics company. IPO in January 2022 (NASDAQ: VIGL). Acquired by Sanofi in 2025.

“It is not the critic who counts: not the man who points out how the strong man stumbles or where the doer of deeds could have done better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who strives valiantly, who errs and comes up short again and again, because there is no effort without error or shortcoming, but who knows the great enthusiasms, the great devotions, who spends himself in a worthy cause; who, at the best, knows, in the end, the triumph of high achievement, and who, at the worst, if he fails, at least he fails while daring greatly, so that his place shall never be with those cold and timid souls who knew neither victory nor defeat.”


Theodore Roosevelt
Speech at the Sorbonne, Paris, April 23, 1910